Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1951 4
1952 13
1953 19
1954 13
1955 15
1956 9
1957 13
1958 12
1959 4
1961 1
1964 5
1965 12
1966 20
1967 37
1968 33
1969 50
1970 54
1971 59
1972 63
1973 90
1974 99
1975 94
1976 111
1977 81
1978 78
1979 94
1980 142
1981 115
1982 103
1983 150
1984 165
1985 186
1986 197
1987 226
1988 240
1989 209
1990 295
1991 253
1992 273
1993 323
1994 388
1995 412
1996 532
1997 566
1998 555
1999 640
2000 768
2001 785
2002 863
2003 1080
2004 1117
2005 1212
2006 1257
2007 1419
2008 1401
2009 1553
2010 1685
2011 1835
2012 2038
2013 2167
2014 2147
2015 2119
2016 2115
2017 2084
2018 2098
2019 2189
2020 2197
2021 2121
2022 1965
2023 1838
2024 586

Text availability

Article attribute

Article type

Publication date

Search Results

41,927 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Malignant tumor of prostate"
Page 1
Metastatic Prostate Cancer: Treatment Options.
Achard V, Putora PM, Omlin A, Zilli T, Fischer S. Achard V, et al. Oncology. 2022;100(1):48-59. doi: 10.1159/000519861. Epub 2021 Nov 15. Oncology. 2022. PMID: 34781285 Review.
BACKGROUND: Metastatic prostate cancer (PCa) is associated with considerable diminished overall survival (OS). ...SUMMARY: The advent of novel therapeutic agents has changed this paradigm, with high-level evidence that upfront combination therapy with either docetaxel or n …
BACKGROUND: Metastatic prostate cancer (PCa) is associated with considerable diminished overall survival (OS). ...SUMMARY: The advent …
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; STAMPEDE investigators. Attard G, et al. Lancet Oncol. 2023 May;24(5):443-456. doi: 10.1016/S1470-2045(23)00148-1. Lancet Oncol. 2023. PMID: 37142371 Free article.
FINDINGS: Between Nov 15, 2011, and Jan 17, 2014, 1003 patients were randomly assigned to standard of care (n=502) or standard of care plus abiraterone (n=501) in the abiraterone trial. Between July 29, 2014, and March 31, 2016, 916 patients were randomly ass …
FINDINGS: Between Nov 15, 2011, and Jan 17, 2014, 1003 patients were randomly assigned to standard of care (n=502) or standard of car …
Treatment of the primary tumor in metastatic prostate cancer.
Yuan Y, Kishan AU, Nickols NG. Yuan Y, et al. World J Urol. 2019 Dec;37(12):2597-2606. doi: 10.1007/s00345-018-2552-8. Epub 2018 Nov 19. World J Urol. 2019. PMID: 30456709 Review.
The cornerstone of treatment for metastatic prostate cancer patients has been conventional androgen deprivation therapy, with additional systemic therapy initiated only after castration resistance, and local therapy reserved for palliation. ...As such, the landscape is pri …
The cornerstone of treatment for metastatic prostate cancer patients has been conventional androgen deprivation therapy, with additio …
Inmunotherapy in prostate cancer.
Anselmo da Costa I, Stenzl A, Bedke J. Anselmo da Costa I, et al. Arch Esp Urol. 2019 Mar;72(2):211-222. Arch Esp Urol. 2019. PMID: 30855023 Free article. Review. English.
Prostate cancer (PCa) is the second most commonly diagnosed cancer. ...The low grade of toxicity associated with these immunotherapies is an appealing advantage for patients, leading to an increased appreciation of theses types of treatments. Until now, only one clinica …
Prostate cancer (PCa) is the second most commonly diagnosed cancer. ...The low grade of toxicity associated with these immunotherapie …
Genetic Testing in Prostate Cancer.
Sokolova AO, Cheng HH. Sokolova AO, et al. Curr Oncol Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11912-020-0863-6. Curr Oncol Rep. 2020. PMID: 31974718 Free PMC article. Review.
Emerging data indicate that platinum chemotherapy and poly ADP-ribose polymerase inhibitors (PARPi) are effective in PCa exhibiting HR deficiency. NCCN guidelines now recommend germline and somatic tumor testing in specific clinical scenarios due to treatment and fa …
Emerging data indicate that platinum chemotherapy and poly ADP-ribose polymerase inhibitors (PARPi) are effective in PCa exhibiting HR defic …
The Emerging Role of Local Therapy in Metastatic Prostate Cancer.
Sundahl N, Tree A, Parker C. Sundahl N, et al. Curr Oncol Rep. 2020 Jan 20;22(1):2. doi: 10.1007/s11912-020-0868-1. Curr Oncol Rep. 2020. PMID: 31960153 Review.
PURPOSE OF REVIEW: This review summarizes the prospective clinical evidence regarding local therapy in metastatic prostate cancer. RECENT FINDINGS: The phase 3 STAMPEDE trial showed that prostate radiotherapy confers a survival benefit for newly diagno …
PURPOSE OF REVIEW: This review summarizes the prospective clinical evidence regarding local therapy in metastatic prostate can …
Immunotherapy in prostate cancer.
Sobol I, Thompson RH, Dong H, Krco C, Kwon ED. Sobol I, et al. Curr Urol Rep. 2015 Jun;16(6):34. doi: 10.1007/s11934-015-0509-7. Curr Urol Rep. 2015. PMID: 25894495 Review.
Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. ...Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized …
Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. ...Sipuleucel-T i …
Adjuvant therapy in high-risk prostate cancer.
Shevach J, Chaudhuri P, Morgans AK. Shevach J, et al. Clin Adv Hematol Oncol. 2019 Jan;17(1):45-53. Clin Adv Hematol Oncol. 2019. PMID: 30843898 Review.
Although the prognosis in patients with localized prostate cancer is positive overall, high-risk localized disease is responsible for significant cancer-related morbidity and mortality following local treatment failure. Despite recent medical advances in advanced prosta …
Although the prognosis in patients with localized prostate cancer is positive overall, high-risk localized disease is responsible for …
PARP Inhibition in Advanced Prostate Cancer.
Fenton SE, Chalmers ZR, Hussain M. Fenton SE, et al. Cancer J. 2021 Nov-Dec 01;27(6):457-464. doi: 10.1097/PPO.0000000000000560. Cancer J. 2021. PMID: 34904808 Review.
Loss-of-function mutations in genes such as BRCA1 and BRCA2 increase reliance on PARP-mediated mechanisms of DNA repair, and inhibition of this pathway results in the accumulation of lethal levels of DNA damage. This dependence is advantageous in the management of prostate …
Loss-of-function mutations in genes such as BRCA1 and BRCA2 increase reliance on PARP-mediated mechanisms of DNA repair, and inhibition of t …
Contemporary treatments in prostate cancer focal therapy.
Ahdoot M, Lebastchi AH, Turkbey B, Wood B, Pinto PA. Ahdoot M, et al. Curr Opin Oncol. 2019 May;31(3):200-206. doi: 10.1097/CCO.0000000000000515. Curr Opin Oncol. 2019. PMID: 30865133 Free PMC article. Review.
Advances in the field of prostate MRI and desire to reduce treatment morbidities have led to a rapid growth in focal treatments for prostate cancer. Here, we review novel focal prostate cancer treatments and their associated recent clinical data, with …
Advances in the field of prostate MRI and desire to reduce treatment morbidities have led to a rapid growth in focal treatments for …
41,927 results
You have reached the last available page of results. Please see the User Guide for more information.